Response-adapted sequential azacitidine and induction chemotherapy in patients >60 years old with newly diagnosed AML eligible for chemotherapy. Results of the DRKS00004519 study of the East German Study Group

被引：0
|
作者：
Jaekel, N. [1 ]
Hubert, K. [2 ]
Krahl, R. [1 ]
Hanel, M. [3 ]
Maschmeyer, G. [4 ]
Herbst, R. [5 ]
Jakob, C. [4 ]
Schulze, S. [1 ]
Wang, S. -Y. [1 ]
Cross, M. [1 ]
Kahl, C. [6 ]
Wass, M. [2 ]
Sayer, H. G. [7 ]
Brosteanu, O. [8 ]
Niederwieser, D. [1 ]
Al-Ali, H. K. [2 ]
机构：
[1] Uniklin Leipzig, Hamatol & Internist Onkol, Leipzig, Germany
[2] Univ Klinikum Halle, Hamatol & Internist Onkol, Halle, Germany
[3] Klinikum Chemnitz, Hamatol & Internist Onkol, Chemnitz, Germany
[4] Klinikum Ernst Bergmann, Abt Hamatol Onkol, Potsdam, Germany
[5] Klinikum Chemnitz, Abt Hamatol Onkol, Chemnitz, Germany
[6] Klinikum Magdeburg, Abt Hamatol Onkol, Magdeburg, Germany
[7] HELIOS Klinikum Erfurt, Hamatol & Internist Onkol, Erfurt, Germany
[8] Zentrum Klin Studien Leipzig, Leipzig, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V133
引用
收藏
页码：27 / +
页数：2
相关论文
共 42 条
  • [31] Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort
    Esteve, Jordi
    Schots, Rik
    Del Castillo, Teresa Bernal
    Lee, Je-Hwan
    Wang, Eunice S.
    Dinner, Shira
    Minden, Mark D.
    Salamero, Olga
    Sierra, Jorge
    Yoshimoto, Goichi
    Laribi, Kamel
    Halka, Janusz
    Montesinos, Pau
    Liu, Shufang
    Rich, Elizabeth Shima
    Bahceci, Erkut
    BLOOD, 2018, 132
  • [32] A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group Study #9617.
    Chauncey, TR
    Rankin, C
    Anderson, JE
    Godwin, JA
    Kalaycio, M
    Moore, DF
    Petersdorf, SH
    Shurafa, MS
    Kraut, EH
    Head, DR
    Slovak, ML
    Willman, CL
    Appelbaum, FR
    BLOOD, 1998, 92 (10) : 231A - 231A
  • [33] Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
    Amadori, Sergio
    Suciu, Stefan
    Selleslag, Dominik
    Stasi, Roberto
    Alimena, Giuliana
    Baila, Liliana
    Rizzoli, Vittorio
    Borlenghi, Erika
    Gaidano, Gianluca
    Magro, Domenico
    Torelli, Giuseppe
    Muus, Petra
    Venditti, Adriano
    Cacciola, Emma
    Lauria, Francesco
    Vignetti, Marco
    de Witte, Theo
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) : 376 - 382
  • [34] Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis
    Kim, Jin Seok
    Suh, Cheolwon
    Cheong, June-Won
    Kim, Kihyun
    Kim, Yang Soo
    Lee, Se-Ryeon
    Bae, Sung Hwa
    Joo, Young-Don
    Lee, Sang Min
    Eom, Hyeon Seok
    Park, Eunkyung
    Yoon, Sung-Soo
    Kim, Inho
    Kwak, Jae-Yong
    Min, Chang-Ki
    Kim, Jeong-A
    Park, Moo-Rim
    Kim, Sung Hyun
    Kang, Hye Jin
    Kim, Min Kyoung
    Kim, Hawk
    Mun, Yeung-Chul
    Kim, Hoon-Gu
    Lee, Moon Hee
    Lee, Jae Hoon
    BLOOD, 2011, 118 (21) : 896 - 897
  • [35] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with Diffuse Large B-cell Lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)
    Schubert, J.
    Ziepert, M.
    Lengfelder, E.
    Mohren, M.
    Peter, N.
    Reiser, M.
    Clemens, M.
    Nickenig, C.
    Bokemeyer, C.
    Ho, A. D.
    Eimermacher, H.
    Truemper, L.
    Hoffmann, M.
    Mertelsmann, R.
    Metzner, B.
    Mergenthaler, H. -G.
    Liersch, R.
    Duehrsen, U.
    Balleisen, L.
    Hartmann, F.
    Poeschel, V.
    Schmitz, N.
    Loeffler, M.
    Pfreundschuh, M.
    ONKOLOGIE, 2008, 31 : 120 - 120
  • [36] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
    Schubert, Joerg
    Ziepert, Marita
    Lengfelder, Eva
    Mohren, Martin
    Peter, Norma
    Reiser, Marcel
    Clemens, Michael
    Nickenig, Christina
    dewit, Maike
    Ho, Anthony
    Eimermacher, Hartmut
    Truemper, Lorenz
    Hoffmann, Martin
    Mertelsmann, Roland
    Metzner, Bernd
    Mergenthaler, Hans-Guenther
    Liersch, Ruediger
    Duehrsen, Ulrich
    Balleisen, Leopold
    Hartmann, Frank
    Poeschel, Viola
    Schmitz, Norbert
    Loeffler, Markus
    Pfreundschuh, Michael
    BLOOD, 2007, 110 (11) : 242A - 242A
  • [37] AML -THERAPY: PROGNOSTIC IMPACT OF DAY 15 BLAST CLEARANCE IN RISK-ADAPTED REMISSION INDUCTION CHEMOTHERAPY FOR YOUNGER PATIENTS WITH ACUTE MYELOID LEUKEMIA: LONG TERM RESULTS OF THE MULTICENTER PROSPECTIVE LAM-2001 TRIAL BY THE GOELAMS STUDY GROUP
    Bertoli, Sarah
    ANNALS OF HEMATOLOGY, 2013, 92 : S3 - S4
  • [38] Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study
    Kiefer, T.
    Hirt, C.
    Montemurro, M.
    Schueler, F.
    Spaeth, C.
    Al-Ali, H. K.
    Wolf, H. H.
    Herbst, R.
    Haas, A.
    Helke, K.
    Kessler, C.
    Niederwieser, D.
    Schwenke, M.
    Schroeder, H.
    Vogelgesang, S.
    Krueger, W. H.
    Doelken, G.
    ONKOLOGIE, 2011, 34 : 130 - 131
  • [39] Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study
    Kiefer, T.
    Hirt, C.
    Spaeth, C.
    Schueler, F.
    Al-Ali, H. K.
    Wolf, H. -H.
    Herbst, R.
    Maschmeyer, G.
    Helke, K.
    Kessler, C.
    Niederwieser, D.
    Busemann, C.
    Schroeder, H.
    Vogelgesang, S.
    Kirsch, M.
    Montemurro, M.
    Krueger, W. H.
    Doelken, G.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1809 - 1812
  • [40] Sequential induction chemotherapy with high dose daunorubicin (90mg/m2/d x3) and high dose cytarabine (3g/m2/12hr x 6 doses) in newly diagnosed AML -: Results of a pilot study.
    Saikia, T
    Advani, SH
    BLOOD, 2001, 98 (11) : 221B - 221B
12345